Alantolactone is a
sesquiterpene lactone isolated from Inula helenium L. Although
alantolactone possesses anti-
inflammation and apoptosis-induction activities, the underlying mechanism of anti-
cancer effect on human
breast cancer cells remains largely unknown. In this study, we explored the possibility of
alantolactone as an apoptosis-inducing
cytotoxic agent using MDA-MB-231 cells as in vitro model.
Alantolactone significantly induced its apoptosis, demonstrated by cell cycle analysis,
annexin V-APC/7-AAD double staining and dUTP nick end labeling. Additionally,
alantolactone triggered the mitochondrial-mediated
caspase cascade apoptotic pathway, which was confirmed by increased Bax/Bcl-2 ratio, loss of
MMP, release of cytc from mitochondria to cytoplasm, activation of
caspase 9/3, and subsequent cleavage of PARP.
Z-VAD-FMK partially prevented apoptosis induced by
alantolactone.
Alantolactone provoked the production of ROS, while NAC (a scavenger of ROS) reversed
alantolactone-mediated depolarization of
MMP and apoptosis.
Alantolactone modulated the activities of MAPKs. As expected, cotreatment with
SB203580,
SP600125 or
U0126 could reduced the apoptotic rate. Furthermore,
alantolactone decreased the
protein expressions of p-
NF-kB p65 and p-STAT3, increased p-c-Jun level in a dose-dependent manner. These findings suggested that
alantolactone possessed anticancer activity via ROS-mediated
mitochondrial dysfunction involving MAPK pathway, and had an effect on the
transcription factors of
NF-kB,
AP-1 and STAT3.